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B A C K G R O U N D :  Limited information about the preva-
lence of drug-resistant tuberculosis (TB) has been reported 
from India, the country with the world’s highest burden 
of TB. We conducted a representative state-wide survey 
in the state of Gujarat (2005 population: 56 million). 
M E T H O D S :  Mycobacterium tuberculosis isolates from 
a representative sample of new and previously treated 
smear-positive pulmonary TB (PTB) cases were subjected 
to drug susceptibility testing (DST) against fi rst-line drugs 
at a World Health Organization supranational reference 
laboratory. Isolates found to have at least both isoniazid 
(INH) and rifampicin (RMP) resistance (i.e., multidrug-
resistant TB [MDR-TB]) were subjected to second-line 
DST. 
R E S U LT S :  Of 1571 isolates from new patients, 1236 
(78.7%) were susceptible to all fi rst-line drugs, 173 (11%) 
had any INH resistance and MDR-TB was found in 37 
(2.4%, 95%CI 1.6–3.1). Of 1047 isolates from previ-
ously treated patients, 564 (54%) were susceptible to all 
fi rst-line drugs, 387 (37%) had any INH resistance and 
MDR-TB was found in 182 (17.4%, 95%CI 15.0–19.7%). 
Among 216 MDR-TB isolates, 52 (24%) were ofl oxacin 
(OFX) resistant; seven cases of extensively drug-resistant 
TB (XDR-TB) were found, all of whom were previously 
treated cases. 
C O N C L U S I O N :  MDR-TB prevalence remains low among 
new TB patients in Gujarat, but is more common among 
previously treated patients. Among MDR-TB isolates, 
the alarmingly high prevalence of OFX resistance may 
threaten the success of the expanding efforts to treat 
and control MDR-TB. 
K E Y  W O R D S :  tuberculosis; drug resistance; India
THE FOURTH GLOBAL REPORT on Anti-tubercu-
losis Drug Resistance Surveillance found that the pro-
portion of reported tuberculosis (TB) cases that ex-
hibited any antibiotic resistance ‘ranged from 0% in 
two Western European countries to 56.3% in Baku, 
Azerbaijan’.1 The overall proportion of multidrug-
resistant tuberculosis (MDR-TB), defi ned as TB resis-
tant to at least isoniazid (INH) and rifampicin (RMP), 
with or without resistance to other fi rst-line drugs, 
was 5.3%, ranging from 0% to 35% of reported TB 
cases. Based on the survey data, the World Health 
Organization (WHO) estimates that, globally, nearly 
half a million new cases of MDR-TB occur each year.2 
The report also found that extensively drug-resistant 
TB (XDR-TB), i.e., MDR-TB with resistance to a fl uo-
roquinolone (FQ) and one of the injectable second-
line drugs, which is more expensive and diffi cult to 
treat than MDR-TB, is widespread, with 45 coun-
tries having reported at least one case.1 However, the 
WHO report cautions that few countries are currently 
equipped to diagnose XDR-TB, and it is therefore 
diffi cult to estimate the true extent of XDR-TB.2
India has the world’s highest burden of TB (approx-
imately 3.4 million cases), accounting for one fi fth of 
global incident cases, and ranks fi rst among the 22 TB 
high-burden countries.3 Drug-resistant TB (DR-TB) 
has frequently been encountered in India, and its pres-
ence has been known since anti-tuberculosis drugs 
were fi rst introduced for the treatment of TB. Most 
previous reports on drug resistance from India are 
from tertiary level care, and are thus not representa-
tive of the TB situation in India.4 These reports are 
therefore of little use for the planning purposes of the 
Government of India’s Revised National Tuberculo-
sis Control Programme (RNTCP). 
To guide the RNTCP, the fi rst representative drug 
resistance survey was undertaken in Gujarat in 2005–
2006, and the results are reported here.
S U M M A R Y
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METHODS
Setting
The state of Gujarat, in the northwest of India, has a 
population of almost 56 million (2005). Gujarat be-
gan implementing the RNTCP in a phased manner in 
1998, achieving state-wide coverage in April 2004. 
In 2006, over 77 000 patients were registered under 
the RNTCP in Gujarat, with a case detection rate of 
69% and a treatment success rate of 86% among 
new smear-positive pulmonary TB (PTB) cases.5 The 
laboratory used for the survey was the Tuberculosis 
Research Centre (TRC), Chennai, a WHO-designated 
Supranational Mycobacteriology Reference Labora-
tory, South-East Asian Region, and the National Ref-
erence Laboratory for the RNTCP. The survey was 
conducted with ethical approval from the RNTCP. 
Training was given to all staff on all aspects of the 
survey, including collection, biosafe packing and trans-
port of specimens, patient information and treatment 
history (to prevent misclassifi cations). The minimum 
and maximum delays in receiving specimens ranged 
from 2 to 66 days, with 80–90% of specimens re-
ceived within 7–10 days (recovery rates from speci-
mens transported in cetylpyridinium chloride [CPC] 
are being reported separately). The history of treat-
ment was carefully collected and verifi ed indepen-
dently during the survey period, as the programme 
also performs routine monitoring (internal evalua-
tions) of district level programmes that specifi cally 
looks at this issue. Minimal misclassifi cations were 
found in Gujarat. 
Deﬁ nitions
Resistance defi nitions were used as per the WHO 
guidelines.6 
Study design 
This was a cross-sectional cluster survey to estimate 
the prevalence of drug resistance among Mycobacte-
rium tuberculosis isolates recovered from new and 
previously treated smear-positive PTB cases diagnosed 
in RNTCP microscopy centres in Gujarat, India, from 
November 2005 to October 2006. The survey was 
conducted in accordance with international recom-
mendations for drug resistance surveillance.6
The basic sampling unit for clusters was the 
RNTCP microscopy centre. A sample size of 1680 
new and 992 previously treated cases was estimated 
based on an expected MDR-TB prevalence of respec-
tively 2% and 12%, with 50% precision, 10% loss 
and design effect of 2. Of 630 RNTCP microscopy 
centres, 52 (27 rural and 25 urban) were randomly se-
lected after weighting by number of new cases; selected 
centres were assigned a fi xed sample size per micros-
copy centre of 32 consecutive new smear-positive 
cases. Specimens obtained from patients suspected of 
TB were evaluated by Ziehl-Neelsen (ZN) at the mi-
croscopy centres; two additional specimens were col-
lected from those patients with positive sputum smear 
results for culture and drug susceptibility testing 
(DST). Human immunodefi ciency virus (HIV) testing 
was not done as part of the survey, as it was not pol-
icy at the time. 
Treating physicians used a standardised reporting 
form to interview the smear-positive patients and ab-
stracted medical records for information on history 
of previous anti-tuberculosis drug use. At each micros-
copy centre, enrolment continued of all consecutive 
smear-positive patients (new and previously treated) 
until a sample size of 32 new patients was reached. 
Forms were sent to the TRC, double-entered and ana-
lysed using Epi Info 6.04d (Centers for Disease Pre-
vention and Control, Atlanta, GA, USA).
Culture and DST procedures
Sputum specimens, collected from eligible smear-
positive patients at the microscopy centres in Mc-
Cartney bottles with 1% CPC/2% sodium chloride, 
were transported to the reference laboratory. Concen-
trated deposit smears were prepared and stained with 
auramine phenol. Culture and DST were performed 
using solid Löwenstein-Jensen (LJ) media as per the 
National Drug Resistance Surveillance Survey Proto-
col.7 For DST, pure drug powders are procured from 
Sigma Aldrich India Ltd., Bangalore, and the eco-
nomic variant of the indirect proportion method was 
used, with critical concentrations of INH 0.2 μg/ml, 
streptomycin (SM) 4 μg/ml, RMP 40 μg/ml and eth-
ambutol (EMB) 2 μg/ml. For internal quality control 
(IQC), each batch of DST for all drugs tested was ac-
companied by an H37Rv strain which was tested with 
the lower concentrations, along with one strain with 
known resistance to each drug.8 In addition, DST was 
performed using two methods (proportion sensitivity 
and absolute concentration methods) for the initial 
1200 samples of the survey; there was 98% concor-
dance between the results.
For those isolates that were identifi ed as MDR-
TB, second-line DST for kanamycin (KM), ofl oxacin 
(OFX) and ethionamide (ETH) was conducted on solid 
LJ media using the 1% proportion sensitivity method 
as per WHO guidelines,9 using minimum critical con-
centrations of respectively 30 μg/ml, 2.0 μg/ml and 
40 μg/ml. The IQC procedures followed were as for 
fi rst-line DST. Profi ciency testing for second-line drugs 
with the Supranational Reference Laboratory in Ant-
werp, Belgium, was available post-survey and had an 
agreement of >90%. 
RESULTS
A total of 2674 patients (1979 males and 695 fe-
males) were enrolled and had specimens collected 
and sent to the TRC, including 1638 (61%) from 
new patients and 1126 (39%) from previously treated 
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patients. Overall smear positivity was 98.5%: 97% 
were smear- and culture-positive, 0.9% smear-negative 
and culture-positive, 1.8% were smear-positive and 
culture-negative and 0.7% were smear- and culture-
negative. M. tuberculosis was recovered from re-
spectively 1582 (97%) and 1067 (95%) new and pre-
viously treated cases. Of these, DST results were 
available from 1571 (99.3%) new and 1047 (98.1%) 
previously treated cases (Table 1). There were no sig-
nifi cant differences in drug resistance patterns and 
age-sex distribution (data not shown). Smear positiv-
ity concordance between the ZN and fl uorescent mi-
croscopy smears at the RNTCP microscopy centres 
and the TRC was 98.5%. 
Resistance to ﬁ rst-line anti-tuberculosis drugs
Among new patients, 79% of all isolates were fully 
susceptible and 21% showed any resistance. Any INH 
resistance was 11% (95% confi dence interval [CI] 
9.4–12.5), and the prevalence of MDR-TB was 2.4% 
(95%CI 1.6–3.1). Resistance to INH, EMB and/or 
SM was 3% (95%CI 2.4– 4.2); RMP resistance other 
than MDR-TB was rare, with just 0.2% monoresis-
tance (Table 1).
Among previously treated patients, 54% of all 
isolates were fully susceptible and 46% showed any 
resistance. The prevalence of drug resistance was 
markedly higher than in the new patients. Any INH 
resistance was found in 37% (95%CI 34.0–39.8) and 
the prevalence of MDR-TB was 17.4% (95%CI 15.0–
19.7). Similarly, compared to new patients, four-drug 
resistance (6.6%) was more common in previously 
treated patients (Table 1).
Second-line drug resistance among MDR-TB cases
A total of 219 MDR-TB cases were detected in the 
survey, of which respectively 37 and 182 were new 
and previously treated cases. The 216 second-line drug 
patterns available are shown in Table 2. Any resis-
tance to OFX was found in 52 (24%, 95%CI 18.1–
29.4) isolates. There was no signifi cant difference in 
any OFX resistance between isolates from new or 
Table 1 Prevalence of ﬁ rst-line anti-tuberculosis drug resistance among M. tuberculosis isolates 
from new and previously treated patients, Gujarat, India, November 2005–October 2006
New cases Previously treated
n (%) 95%CI n (%) 95%CI
Total patients with DST results 1571 (100) 1047 (100)
 Susceptible to all four drugs 
  (H+R+E+S) 1236 (78.7)  564 (53.9)
Any resistance  335 (21) 19.3–23.4  485 (46.3) 43.1–49.2
 H  173 (11)  9.4–12.6  387 (37.0) 34.0–39.9
 R   40 (2.5)  1.8–3.3  192 (18.0) 16.0–20.0
 E   30 (1.9)  1.2–2.6  107 (10.2)  8.4–12.0
 S  228 (15) 12.8–16.3  276 (26.4) 23.7–29.0
Monoresistance  246 (15.7) 13.9–17.5  220 (21) 18.5–23.5
 H only   84 (5.4)  4.2–6.5  122 (11.7)  9.7–13.6
 R only    3 (0.2 ) 0.03–0.4   10 (1.0)  0.4–1.5
 E only    3 ( 0.2) 0.03–0.4    0  0
 S only  156 (10.0)  8.5–11.4   88 (8.4)  6.7–10.0
MDR-TB   37 (2.4)  1.6–3.1  182 (17.4) 15.0–19.7
 Resistant to all 4 drugs
  (H+R+E+S)   13 (0.8 )  0.4–1.3   69 (6.6)  5.1–10.0
Other patterns   52 (3)  2.4–4.2   83 (8)  6.3–9.6
 H+E    3 (0.2) 0.03–0.4    7 (0.7) 0.18–1.2
 H+S   45 (2.9)  2.0–3.7   66 (6)  4.8–7.8
 H+E+S    4 (0.3)    0–0.5   10 (1)  0.4–1.6
CI = conﬁ dence interval; DST = drug susceptibility testing; H = isoniazid; R = rifampicin; E = ethambutol; S = strep-
tomycin; MDR-TB = multidrug-resistant tuberculosis (deﬁ ned as resistance to at least H and R).
Table 2 Prevalence of second-line drug resistance amongst 
multidrug-resistant M. tuberculosis isolates, Gujarat, India, 
November 2005–October 2006
Second-line DST
New cases 
(n = 37)
n (%)
Previously 
treated cases
(n = 179) 
n (%)
Total
(N = 216) 
n (%)
Susceptible to all 
 second-line drugs 
 tested (OFX, KM, ETH) 18 (48.6) 101 (56.4) 119 (55.0)
Any resistance 19 (51.4)  75 (42.0)  94 (43.5)
 KM  0   7 (4.0)   7 (3.2)
 OFX  7 (19.0)  45 (25.0)  52 (24.0)
 ETH 15 (40.5)  45 (25.0)  60 (28.0)
Monoresistance 16 (43.2)  56 (31.0)  72 (33.0)
 KM only  0   0   0
 OFX only  4 (11.0)  30 (17.0)  34 (16.0)
 ETH only 12 (32.4)  26 (14.5)  38 (17.5)
XDR-TB  0   7 (4.0)   7 (3.0)
 KM+OFX  0   4 (2.2)   4 (1.8)
 KM+OFX+ETH  0   3 (1.7)   3 (1.4)
Other patterns  3 (8.0)  12 (7.0)  15 (7.0)
 OFX+ETH  3 (8.0)  12 (7.0)  15 (7.0)
DST = drug susceptibility testing; OFX = oﬂ oxacin; KM = kanamycin; ETH = 
ethionamide; XDR-TB = extensively drug-resistant TB (deﬁ ned as an MDR-TB 
isolate also resistant to OFX and a second-line injectable class drug [e.g., 
KM]); MDR-TB = multidrug-resistant tuberculosis.
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previously treated MDR-TB cases. Any resistance to 
ETH was found in 60 (27.8%, 95%CI 21.5–33.3) 
isolates, and was slightly more common among new 
MDR-TB cases compared to previously treated MDR-
TB cases (relative risk [RR] 1.6, 95%CI 1.0–2.6). 
KM resistance was very uncommon, being found in 
only seven isolates (3.2%, 95%CI 0.9–5.5), all of 
which also had OFX resistance, and were thus classi-
fi ed as XDR-TB (3% of the total MDR-TB isolates). 
All instances of KM resistance and XDR-TB occurred 
in previously treated cases.
DISCUSSION
This is the largest population-based survey of the prev-
alence of drug-resistant TB to date from India, repre-
sentative of TB patients treated under the RNTCP in 
Gujarat. We detected a low prevalence of MDR-TB 
among new patients (2.4%), similar to that previ-
ously reported, and much lower than reported from 
other high TB burden countries from the former So-
viet Union2 and China.10 The prevalence of any resis-
tance to INH (11%), SM (15.0%), RMP (2.5%) and 
EMB (2.0%) and MDR-TB observed among new cases 
are similar to levels seen in other previous district-
level reports.4,11–13 Levels of mono- and polyresistance 
are also lower than in most previous reports from 
India.14,15 The fi ndings from this survey and the con-
sistency with previously reported results support the 
interpretation that standard short-course chemother-
apy is likely to remain highly effective among the 
great majority of new TB patients in India.
For the fi rst time, this survey provides a precise in-
dication of the prevalence of drug resistance from a 
representative sample of previously treated patients 
in India. We found that 17.4% of previously treated 
patients had MDR-TB, and 6.6% had four-drug resis-
tance. In 2006, more than 190 000 patients were regis-
tered as smear-positive PTB retreatment cases in India.5 
The WHO has estimated that over 110 000 MDR-TB 
cases emerged in India in 2006.1 The RNTCP has ac-
knowledged that, although MDR-TB cases represent 
a smaller proportion of the overall TB caseload in 
India, they constitute an ongoing problem for the pro-
gramme from both an epidemiological and a human 
rights viewpoint.16 The RNTCP has therefore devel-
oped a response plan that aims to continue strength-
ening the programme’s preventive activities against the 
development of ‘new’ MDR-TB cases by providing 
high-quality DOTS services and introducing RNTCP 
DOTS-Plus Category IV services for MDR-TB cases in 
a phased manner across the country. The fi rst MDR-
TB patients were registered for RNTCP Category IV 
treatment in August 2007 in Gujarat itself.17 Reach-
ing all the smear-positive retreatment patients with 
culture and DST services, and treatment for those 
identifi ed with MDR-TB, will be crucial to accelerate 
and sustain effective TB control efforts in India. 
The strengths of this survey are its scale and repre-
sentativeness and the inclusion of large numbers of 
previously treated patients. Most previous reports on 
anti-tuberculosis drug resistance from India have been 
from hospitals or tertiary care centres, and hence have 
not been representative of the wider community of TB 
patients. A small number of district-wide representa-
tive surveys carried out by the TRC and the National 
Tuberculosis Institute (NTI), Bangalore, between 1998 
and 2002, covered much smaller geographical areas. 
The results reported here are quite consistent with 
those previously reported from the state of Gujarat18,19 
and other geographical areas throughout India.4
What are the risks of MDR-TB increasing in In-
dia? During the survey period, the RNTCP in Gu-
jarat consistently achieved a new smear-positive case 
detection rate of over 70%, with a success rate of over 
85%. Of the 2006 patient cohort, only 2.6% of new 
smear-positive cases failed treatment, suggesting that 
the thrice-weekly intermittent standard short-course 
chemotherapy regimen remains effective in India.5 The 
elevated proportion of MDR-TB among previously 
treated cases also includes some chronic cases but, 
more importantly, a large proportion of retreatment 
patients were previously treated outside the RNTCP 
(80% of the patients are from the private sector and 
the non-RNTCP public sector), many of whom have 
received suboptimal TB treatment.20 Treatment out-
comes for previously treated cases in Gujarat are not 
satisfactory. While low treatment success among these 
patients is primarily due to high levels of default (20–
24% in 2005–2006), it is also likely that high levels 
of any drug resistance (46%) and resistance to INH 
(37%) and SM (26%) played an important role.17 
Expanding access to culture and DST services for all 
smear-positive previously treated patients could be 
an effi cient strategy to detect MDR-TB, initiate early 
treatment and prevent further transmission, as is be-
ing planned by the RNTCP.
Among MDR-TB isolates, we detected an alarming 
and unprecedented prevalence of any resistance to 
OFX of 24% (95%CI 18.4–29.7), which was not sig-
nifi cantly different among new and previously treated 
MDR-TB patients (19% vs. 25%, Fisher’s two-tailed 
test, P = 0.56). The high level of resistance to an FQ 
(i.e., OFX in this instance) correlates well with the 
very widespread use of FQs for the treatment of new 
TB cases in the private sector and its irrational use for 
pyrexia of unknown origin (PUO) and respiratory 
infections that could be undiagnosed TB in India. 
This is in line with other reports from elsewhere in 
the world where high rates of resistance to FQs are 
reported.21–23 Case reports have shown that even a 
short duration of monotherapy with a FQ can quickly 
result in acquired resistance in M. tuberculosis.24,25 
Regardless of the reason, resistance to FQs has seri-
ous implications. First, FQs are crucial for the treat-
ment of MDR-TB, and resistance to FQs has been 
1158 The  International  Journal  of  Tuberculosis  and  Lung  Disease
independently associated with poor MDR-TB treat-
ment outcomes.26 Patients with FQ resistance are also 
at risk of developing XDR-TB during treatment with 
second-line drugs, a risk that may increase if these 
drugs are administered outside the setting of a struc-
tured and supportive treatment programme.27 Sec-
ond, Phase III clinical trials are currently evaluating 
the effectiveness of FQs as fi rst-line anti-tuberculosis 
drugs in shorter duration regimens.28 If the preva-
lence of resistance to FQs increases substantially, the 
value of these drugs as an alternative fi rst-line regi-
men could potentially be substantially reduced. 
Although we could only test the MDR isolates 
against KM, resistance to KM was not observed in 
any of the MDR-TB isolates from new cases and was 
detected in only seven (4.0%, 95%CI 1.1–6.7) of the 
previously retreated cases. The level of KM resistance 
in previously treated patients is lower than reported 
elsewhere.29 The low levels of KM resistance seen in 
Gujarat could be due to the very limited use of this 
drug in the private sector, and also because of the ease 
of prescribing an FQ.
Ethionamide (ETH) resistance was also high (28.0% 
overall, respectively 40.5% and 25% among new and 
treated cases). Resistance to ETH is diffi cult to inter-
pret because technical issues with the DST make the 
results of limited reliability. Hence not all observed 
ETH resistance can be attributed to use of this drug 
in clinical settings,30,31 as reported by others,21 and the 
role of cross-resistance with INH due to mutations in 
the inhA gene and others.32,33 A subset of such ETH-
resistant isolates tested for the inhA gene showed a 
40% prevalence of this mutation, which may account 
for the high in vitro resistance to ETH that was ob-
served (unpublished data). 
This survey had several limitations. For logistical 
reasons, isolates were collected only from patients 
who were smear-positive at an RNTCP microscopy 
centre, most of which are located in the public health 
system. Patients diagnosed outside the RNTCP, many 
of whom would not even have undergone smear mi-
croscopy, are not included here at the time of diag-
nosis. However, we also included retreatment pa-
tients, many of whom had no prior experience with 
TB treatment under the RNTCP. In the MDR iso-
lates, only three of the major second-line drugs (ETH, 
KM and OFX) were tested, but the defi nition of 
XDR-TB also includes amikacin (AMK) and capreo-
mycin (CPM) resistance. Our XDR-TB prevalence es-
timate, however, is likely to be accurate, as AMK re-
sistance is highly concordant with KM and separate 
testing is usually not necessary,34 while CPM was not 
available in India until very recently. Diagnostic cen-
tres for enrolment were selected weighted on the 
number of new patients, and only those retreatment 
patients attending the same diagnostic centres were 
enrolled consecutively. However, given the large num-
ber of previously treated patients enrolled and the 
random selection of microscopy centres, this is not 
likely to have affected the representativeness of the 
drug resistance prevalence estimates for previously 
treated patients. 
CONCLUSION
This survey provides the fi rst representative data to 
be reported on drug resistance prevalence at the com-
munity level in India, and of second-line drug resis-
tance patterns amongst the MDR-TB cases identifi ed 
in the survey. The results give an authentic picture of 
the levels of MDR-TB and XDR-TB in the setting 
of the RNTCP in India, and highlights the potential 
threat that the level of ‘pre-XDR-TB’ presents to the 
RNTCP Category IV regimen, due most likely to 
the widespread misuse of OFX outside the RNTCP 
for the treatment of both TB and non-TB patients in 
the country. India’s RNTCP has taken cognisance of 
the high levels of MDR-TB and non-MDR drug resis-
tance among retreatment cases and has developed a 
response plan that aims to continue strengthening the 
programme’s preventive activities against the devel-
opment of ‘new’ MDR-TB cases by provision of high-
quality DOTS services throughout the country, im-
proving public-private partnerships for TB treatment, 
quality assured laboratory services and the intro-
duction of Category IV services for MDR-TB cases in 
the country.
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R É S U M É
C O N T E X T E  :   On ne dispose que d’informations limitées 
au sujet de la prévalence de la tuberculose (TB) à germes 
résistants en provenance de l’Inde, le pays du monde où 
le fardeau de la TB est le plus élevé. Nous avons mené 
une enquête représentative au niveau de l’Etat dans l’Etat 
de Gujarat (population en 2005 : 56 millions).
M É T H O D E S  :   Les isolats de Mycobacterium tuberculo-
sis provenant d’un échantillon représentatif des cas de 
TB pulmonaire (TBP) à bacilloscopie positive, nouveaux 
ou traités antérieurement, ont subi un test de sensibilité 
aux médicaments (DST) à l’égard des médicaments de 
première ligne dans un laboratoire de référence supra-
national de l’Organisation mondiale de la Santé. Les iso-
lats où une multirésistance (TB-MDR, c’est-à-dire une 
résistance au moins à l’égard de l’isoniazide [INH] et de 
la rifampicine [RMP]) a été trouvée ont été soumis à un 
DST pour les médicaments de seconde ligne. 
R É S U LTAT S  :   Sur 1571 isolats provenant de nouveaux 
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cas, 1236 (78,7%) étaient sensibles à l’ensemble des mé-
dicaments de première ligne ; on a décelé n’importe quel 
type de résistance à l’INH dans 173 cas (11%) et on a 
trouvé une TB-MDR dans 37 cas (2,4% ; IC95% 1,6–
3,1). Sur les 1047 isolats provenant de patients traités 
antérieurement, la sensibilité à l’ensemble des médica-
ments de première ligne a été observée dans 564 isolats 
(54%), une résistance quelconque à l’INH dans 387 iso-
lats (37%) et une TB-MDR dans 182 isolats (17,4% ; 
IC95% 15,0–19,7). Parmi les 216 isolats TB-MDR, 
on a observé une résistance à l’ofl oxacine (OFX) dans 
52 cas (24%) et une TB avec germes ultrarésistants (TB-
XDR) dans sept cas, dont tous étaient des cas traités 
antérieurement. 
C O N C L U S I O N  :   A Gujarat, dans les nouveaux cas de TB, 
la prévalence de la TB-MDR reste faible, mais elle est 
plus courante chez les patients traités antérieurement. 
Parmi les isolats de TB-MDR, la prévalence élevée et 
alarmante de la résistance à l’OFX peut mettre en péril 
le succès de l’extension des efforts pour traiter et con-
trôler la TB-MDR.
R E S U M E N
M A R C O  D E  R E F E R E N C I A  :   Existen pocos informes so-
bre la prevalencia de tuberculosis (TB) farmacorresis-
tente en India, el país con la más alta carga de morbili-
dad por esta enfermedad. Se llevó a cabo un estudio 
representativo de alcance estatal en Gujarat (población 
de 56 millones en 2005). 
M É T O D O S  :   En un laboratorio supranacional de referen-
cia de la Organización Mundial de la Salud, se practica-
ron pruebas de sensibilidad a los medicamentos antituber-
culosos de primera línea en una muestra repre sentativa 
de aislados de Mycobacterium tuberculosis provenien-
tes de casos nuevos y casos previamente tratados de tu-
berculosis pulmonar (TBP) con baciloscopia positiva. 
En los aislados que exhibieron resistencia como mínimo 
a isoniazida (INH) y a rifampicina (RMP) (TB-MDR), 
se realizaron además pruebas de sensibilidad a los anti-
tuberculosos de segunda línea. 
R E S U LTA D O S  :   De los 1571 aislados de pacientes nuevos, 
1236 (78,7%) fueron sensibles a todos los antitubercu-
losos de primera línea, 173 (11%) presentaron resisten-
cia a INH y se encontró MDR en 37 (2,4% ; IC95% 1,6–
3,1%). De los 1047 aislados provenientes de pacien tes 
previamente tratados, 564 (54%) fueron sensibles a to-
dos los medicamentos de primera línea, 387 (37%) re-
sistentes a INH y 182 exhibieron MDR (17,4% ; IC95% 
15,0–19,7). De los 216 aislados de TB-MDR, 52 (24%) 
presentaron resistencia a ofl oxacina (OFX) ; se encon-
traron siete casos de TB extensivamente drogorresis-
tente, todos en pacientes con antecedente de tratamiento 
antituberculoso. 
C O N C L U S I Ó N  :   La prevalencia de TB-MDR sigue siendo 
baja en los pacientes diagnosticados como casos nuevos 
de TB en el estado de Gujarat, pero es más frecuente en 
los pacientes previamente tratados. La prevalencia in-
quietantemente alta de resistencia a OFX en los aislados 
de TB-MDR puede poner en peligro el éxito de las ini-
ciativas de ampliación del tratamiento y el control de 
este tipo de TB.
